April 3, 2013 Approval Letter, Hemacord HPC Cord Blood
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
April 3, 2013
Our STN: BL 125397/9
New York Blood Center, Inc.
Attention: Ms. Eva Quinley
310 East 67 Street
New York, NY 10065
Dear Ms. Quinley:
We have approved your request to supplement your biologics license application for Hematopoietic Progenitor Cells, Cord (HPC-C) for a change in the non-proprietary name to HPC, Cord Blood for the final package insert with instructions, the container label, and package label.
Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. In addition, please submit three original paper copies for carton and container final printed labeling. All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.
You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).
Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes this change.
We will include information contained in the above-referenced supplement in your biologics license application file.
Raj K. Puri, M.D., Ph.D.
Division of Cellular and Gene Therapies
Office of Cellular, Tissue and Gene Therapies
Center for BiologicsEvaluation and Research